Knockdown of GLP-1 Receptors in Vagal Afferents Affects Normal Food Intake and Glycemia
The DOI matches its Crossref record; 42 of the 43 references it cites were found in a registry or an index.
Abstract
Nutrient stimulation of enteroendocrine L cells induces the release of the incretin and satiating peptide glucagon-like peptide 1 (GLP-1). The vagus nerve innervates visceral organs and may contribute to the mediation of gut-derived GLP-1’s effects on food intake, energy homeostasis, and glycemic control. To test the hypothesis that vagal afferent neuron (VAN) GLP-1 receptors (GLP-1Rs) are necessary for these effects of endogenous GLP-1, we established a novel bilateral nodose ganglia injection technique to deliver a lentiviral vector and to knock down VAN GLP-1Rs in male Sprague Dawley rats. We found that a full expression of VAN GLP-1Rs is not necessary for the maintenance of long-term energy balance in normal eating conditions. VAN GLP-1R knockdown (kd) did, however, increase meal size and accelerated gastric emptying. Moreover, postmeal glycemia was elevated and insulin release was blunted in GLP-1R kd rats, suggesting that VAN GLP-1Rs are physiological contributors to the neuroincretin effect after a meal. Collectively, our results highlight a crucial role for the VANs in mediating the effects of endogenous GLP-1 on food intake and glycemia and may promote the further development of GLP-1–based therapies.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“GLP-1RAs can exert their local effects by activating vagal dendritic terminals that innervate the gut.418–420”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [418]
In the citing paper
“Peripheral GLP-1/GLP-1RAs may also interact with the CNS indirectly by GLP-1R expressed on vagal afferent fibers, signaling via nodose ganglia (57) to the nucleus tractus solitarii within the brainstem.”
From The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications (2026) · cites this paper as [57]
In the citing paper
“Importantly, knockdown of GLP-1R in VANs increased meal size (39), and abolished the satiating effects of secretagogue-induced GLP-1 release (34).”
From GLP-1 and the Neurobiology of Eating Control: Recent Advances (2025) · cites this paper as [39]
In the citing paper
“Given the role of GLP-1R-expressing VANs in physiological satiation (23, 39)”
From GLP-1 and the Neurobiology of Eating Control: Recent Advances (2025) · cites this paper as [39]
Citations
Cites
Functional and chemical anatomy of the afferent vagal system
Berthoud, H.-R., & Neuhuber, W. L. (2000) · Autonomic Neuroscience · doi:10.1016/s1566-0702(00)00215-0 · Cited by 1,280 · cited 13×
“We measured HPV blood glucose in the fasted and fed conditions in control and GLP-1R kd rats.”
BackgroundInfluentialSensitivity to leptin and susceptibility to seizures of mice lacking neuropeptide Y
Erickson, J. C., Clegg, K. E., & Palmiter, R. D. (1996) · Nature · doi:10.1038/381415a0 · Cited by 1,008 · cited 2×
“Drugs GLP-1(7-36)amide (Bachem H-6795), Ex-4 (Bachem H-8730), and cholecystokinin octapeptide (CCK) (Bachem H-2080) were resuspended in sterile PBS and administered at doses of 33 mg/kg IP (GLP-1), 0.”
BackgroundMethodVilsboll, T., Christensen, M., Junker, A. E., Knop, F. K., & Gluud, L. L. (2012) · BMJ · doi:10.1136/bmj.d7771 · Cited by 970
The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss
Secher, A., Jelsing, J., Baquero, A. F., Hecksher-Sørensen, J., Cowley, M. A., Dalbøge, L. S., Hansen, G., Grove, K. L., Pyke, C., Raun, K., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci75276 · Cited by 961 · cited 2×
“Recent studies, however, have shown that GLP-1R agonists, such as liraglutide, exert their body weight and glucose-lowering effects independent of vagal afferents (45) and do not require VAN GLP-1Rs (17).”
BackgroundAbbott, C. R., Monteiro, M., Small, C. J., Sajedi, A., Smith, K. L., Parkinson, J. R. C., Ghatei, M. A., & Bloom, S. R. (2005) · Brain Research · doi:10.1016/j.brainres.2005.03.011 · Cited by 599 · cited 2×
“Drugs GLP-1(7-36)amide (Bachem H-6795), Ex-4 (Bachem H-8730), and cholecystokinin octapeptide (CCK) (Bachem H-2080) were resuspended in sterile PBS and administered at doses of 33 mg/kg IP (GLP-1), 0.”
BackgroundMethodVagal Sensory Neuron Subtypes that Differentially Control Breathing
Chang, R. B., Strochlic, D. E., Williams, E. K., Umans, B. D., & Liberles, S. D. (2015) · Cell · doi:10.1016/j.cell.2015.03.022 · Cited by 439 · cited 2×
“Drugs GLP-1(7-36)amide (Bachem H-6795), Ex-4 (Bachem H-8730), and cholecystokinin octapeptide (CCK) (Bachem H-2080) were resuspended in sterile PBS and administered at doses of 33 mg/kg IP (GLP-1), 0.”
BackgroundMethodGlucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms
I˙meryüz, N., Yeğen, B. Ç., Bozkurt, A., Coşkun, T., Villanueva-Peñacarrillo, M. L., & Ulusoy, N. B. (1997) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.1997.273.4.g920 · Cited by 432
Qian, S., Chen, H., Weingarth, D., Trumbauer, M. E., Novi, D. E., Guan, X., Yu, H., Shen, Z., Feng, Y., Frazier, E., et al. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.14.5027-5035.2002 · Cited by 430 · cited 2×
“Drugs GLP-1(7-36)amide (Bachem H-6795), Ex-4 (Bachem H-8730), and cholecystokinin octapeptide (CCK) (Bachem H-2080) were resuspended in sterile PBS and administered at doses of 33 mg/kg IP (GLP-1), 0.”
BackgroundMethodNeuronal GLP1R mediates liraglutide’s anorectic but not glucose-lowering effect
Sisley, S., Gutierrez-Aguilar, R., Scott, M., D’Alessio, D. A., Sandoval, D. A., & Seeley, R. J. (2014) · Journal of Clinical Investigation · doi:10.1172/jci72434 · Cited by 397 · cited 3×
“Drugs GLP-1(7-36)amide (Bachem H-6795), Ex-4 (Bachem H-8730), and cholecystokinin octapeptide (CCK) (Bachem H-2080) were resuspended in sterile PBS and administered at doses of 33 mg/kg IP (GLP-1), 0.”
BackgroundMethodResultKanoski, S. E., Fortin, S. M., Arnold, M., Grill, H. J., & Hayes, M. R. (2011) · Endocrinology · doi:10.1210/en.2011-0174 · Cited by 347 · cited 5×
“Together, this strengthens the classical view that VAN GLP-1Rs mainly mediate shortterm satiation and may be one of several redundant eating control mechanisms comprising the gut-brain axis (7,9,16,33).”
BackgroundMethodSelf-citation
Research works printed but not linked: 1
- Arnold, 2012, Intraperitoneal (IP) glucagon-like peptide-1 (GLP-1) injections and meals in rats increase intestinal lymphatic GLP-1 similarly, Appetite, 59, e3
Cited by
Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1
Drucker, D. J. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.001 · Cited by 2,170
Glucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
“Vagal afferent GLP-1 receptor knockdown accelerates gastric emptying [518] and vagal afferent denervation [795] or peripheral administration of exendin (9e 39) [794,795] blocks the effect of centrally or peripherally administered GLP-1 on gastric emptying.”
BackgroundSelf-citationGlucagon-like peptide-1 receptor: mechanisms and advances in therapy
Zheng, Z., Zong, Y., Ma, Y., Tian, Y., Pang, Y., Zhang, C., & Gao, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01931-z · Cited by 1,036
“5 418 – 420 This activation holds the ability to modulate food consumption by reducing food intake and conveying signals of satiety to the brain.”
BackgroundButyrate reduces appetite and activates brown adipose tissue via the gut-brain neural circuit
Li, Z., Yi, C.-X., Katiraei, S., Kooijman, S., Zhou, E., Chung, C. K., Gao, Y., van den Heuvel, J. K., Meijer, O. C., Berbée, J. F. P., et al. (2018) · Gut · doi:10.1136/gutjnl-2017-314050 · Cited by 674
Steinert, R. E., Feinle-Bisset, C., Asarian, L., Horowitz, M., Beglinger, C., & Geary, N. (2017) · Physiological Reviews · doi:10.1152/physrev.00031.2014 · Cited by 578
Anxiety, depression, and the microbiome: A role for gut peptides
Lach, G., Schellekens, H., Dinan, T. G., & Cryan, J. F. (2018) · Neurotherapeutics · doi:10.1007/s13311-017-0585-0 · Cited by 573
GLP-1 physiology informs the pharmacotherapy of obesity
Drucker, D. J. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101351 · Cited by 510
Signaling pathways in obesity: mechanisms and therapeutic interventions
Wen, X., Zhang, B., Wu, B., Xiao, H., Li, Z., Li, R., Xu, X., & Li, T. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01149-x · Cited by 410
Kopp, K. O., Glotfelty, E. J., Li, Y., & Greig, N. H. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106550 · Cited by 298
Glucose transporters in the small intestine in health and disease
Koepsell, H. (2020) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-020-02439-5 · Cited by 290
Revisiting the Complexity of GLP-1 Action from Sites of Synthesis to Receptor Activation
McLean, B. A., Wong, C. K., Campbell, J. E., Hodson, D. J., Trapp, S., & Drucker, D. J. (2021) · Endocrine Reviews · doi:10.1210/endrev/bnaa032 · Cited by 289
“28 shRNA targeting the nodose ganglion (NG) GLP-1R in male Sprague Dawley rats (134).”
BackgroundMethodGrasset, E., Puel, A., Charpentier, J., Collet, X., Christensen, J. E., Tercé, F., & Burcelin, R. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.04.013 · Cited by 281
“Insulin secretion and gastric emptying are tightly dependent upon a functional gut-brain-periphery axis (Holst, 2007; Krieger et al., 2015, 2016).”
BackgroundRole of the gut-brain axis in energy and glucose metabolism
Wachsmuth, H. R., Weninger, S. N., & Duca, F. A. (2022) · Experimental & Molecular Medicine · doi:10.1038/s12276-021-00677-w · Cited by 269
Central and peripheral GLP-1 systems independently suppress eating
Brierley, D. I., Holt, M. K., Singh, A., de Araujo, A., McDougle, M., Vergara, M., Afaghani, M. H., Lee, S. J., Scott, K., Maske, C., et al. (2021) · Nature Metabolism · doi:10.1038/s42255-021-00344-4 · Cited by 265
“…inherent complexity of interrogating these widely-distributed systems using pharmacological approaches, compounded by observations that native GLP-1 and pharmacokinetically-optimised therapeutic GLP-1 receptor agonists (GLP-1RAs) suppress eating via apparently divergent signalling pathways 19–25 .”
InfluentialSelf-citationBauer, P. V., Duca, F. A., Waise, T. M. Z., Rasmussen, B. A., Abraham, M. A., Dranse, H. J., Puri, A., O’Brien, C. A., & Lam, T. K. T. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2017.09.019 · Cited by 265
Enterochromaffin 5-HT cells – A major target for GLP-1 and gut microbial metabolites
Lund, M. L., Egerod, K. L., Engelstoft, M. S., Dmytriyeva, O., Theodorsson, E., Patel, B. A., & Schwartz, T. W. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2018.03.004 · Cited by 254
“In fact endogenous intestinal GLP-1 may exert some of its effects such as effects on gastric emptying directly through GLP-1 receptor-expressing afferent vagal neurons as demonstrated by viral mediated knock-down of the GLP-1 receptor in nodose ganglia in rats [58].”
BackgroundRole of the vagus nerve in the development and treatment of diet‐induced obesity
de Lartigue, G. (2016) · The Journal of Physiology · doi:10.1113/jp271538 · Cited by 238
“However, there is evidence from knocking down GLP1 receptor expression in vagal afferent neurons that a vagal afferent pathway mediates GLP1 effects on satiation, gastric emptying, and thermogenesis (Krieger et al. 2016), suggesting that at least the drugs targeting GLP1 receptors could be acting in part through a vag…”
BackgroundLongo, S., Rizza, S., & Federici, M. (2023) · Acta Diabetologica · doi:10.1007/s00592-023-02088-x · Cited by 194
“1 3 of GLP-1 is largely due to its direct actions on pancreatic beta and delta cells, but another vagal signaling pathway may exist that enhances incretin effects [33].”
BackgroundThe metabolic impact of small intestinal nutrient sensing
Duca, F. A., Waise, T. M. Z., Peppler, W. T., & Lam, T. K. T. (2021) · Nature Communications · doi:10.1038/s41467-021-21235-y · Cited by 205
Iwasaki, Y., Sendo, M., Dezaki, K., Hira, T., Sato, T., Nakata, M., Goswami, C., Aoki, R., Arai, T., Kumari, P., et al. (2018) · Nature Communications · doi:10.1038/s41467-017-02488-y · Cited by 200
“To examine the involvement of GLP-1R signaling, Ex(9-39) (200 nmol kg−1) or saline was i.”
InfluentialMetabolic messengers: glucagon-like peptide 1
Gribble, F. M., & Reimann, F. (2021) · Nature Metabolism · doi:10.1038/s42255-020-00327-x · Cited by 199
Egerod, K. L., Petersen, N., Timshel, P. N., Rekling, J. C., Wang, Y., Liu, Q., Schwartz, T. W., & Gautron, L. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2018.03.016 · Cited by 191
“A group of selected gut peptide receptors are expressed in vagal afferents It is well established that a major part of the effects of certain gut hormones such as CCK and GLP-1 is mediated through afferent vagal signaling [10,26,27,31].”
BackgroundSignalling from the periphery to the brain that regulates energy homeostasis
Kim, K.-S., Seeley, R. J., & Sandoval, D. A. (2018) · Nature Reviews Neuroscience · doi:10.1038/nrn.2018.8 · Cited by 183
Glucagon-like Peptide-1 and the Central/Peripheral Nervous System: Crosstalk in Diabetes
Muscogiuri, G., DeFronzo, R. A., Gastaldelli, A., & Holst, J. J. (2017) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2016.10.001 · Cited by 171
The physiological control of eating: signals, neurons, and networks
Watts, A. G., Kanoski, S. E., Sanchez-Watts, G., & Langhans, W. (2022) · Physiological Reviews · doi:10.1152/physrev.00028.2020 · Cited by 168
Self-citationDissociable hindbrain GLP1R circuits for satiety and aversion
Huang, K.-P., Acosta, A. A., Ghidewon, M. Y., McKnight, A. D., Almeida, M. S., Nyema, N. T., Hanchak, N. D., Patel, N., Gbenou, Y. S. K., Adriaenssens, A. E., et al. (2024) · Nature · doi:10.1038/s41586-024-07685-6 · Cited by 166
Adams, J. M., Pei, H., Sandoval, D. A., Seeley, R. J., Chang, R. B., Liberles, S. D., & Olson, D. P. (2018) · Diabetes · doi:10.2337/db17-1385 · Cited by 159
“administration of glucagon-like peptide-1-(7-36) amide or exendin-(9-39) alters”
BackgroundInfluentialSemaglutide as a promising antiobesity drug
Christou, G. A., Katsiki, N., Blundell, J., Fruhbeck, G., & Kiortsis, D. N. (2019) · Obesity Reviews · doi:10.1111/obr.12839 · Cited by 159
“On the contrary, native GLP‐1‐induced decrease in food intake appears to be mediated mainly through a peripheral mechanism, since native GLP‐1 has been found to delay both gastric emptying and gut motility with the subsequent activation of gastric mechano‐receptors to produce satiation signals, which are relayed via t…”
BackgroundClinical Consequences of Delayed Gastric Emptying With GLP-1 Receptor Agonists and Tirzepatide
Jalleh, R. J., Plummer, M. P., Marathe, C. S., Umapathysivam, M. M., Quast, D. R., Rayner, C. K., Jones, K. L., Wu, T., Horowitz, M., & Nauck, M. A. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae719 · Cited by 157
“While the mechanisms by which GLP-1 and GLP-1RAs affect intestinal motility remain to be defined, they appear to inhibit gastrointestinal motor function through both parasympathetic (vagal) afferents and direct central nervous stimulation (85-87).”
Microbiota‐gut‐brain axis as a regulator of reward processes
García‐Cabrerizo, R., Carbia, C., O´Riordan, K. J., Schellekens, H., & Cryan, J. F. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15284 · Cited by 144
“This peptide activates GLP-1 receptors (GLP-1R) present in the dendritic terminals of the vagal afferents acting on the CNS and suppressing food intake (Krieger et al., 2015).”
BackgroundThe metabolic role of vagal afferent innervation
Waise, T. M. Z., Dranse, H. J., & Lam, T. K. T. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0062-1 · Cited by 140
Small talk: microbial metabolites involved in the signaling from microbiota to brain
Caspani, G., & Swann, J. (2019) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2019.08.001 · Cited by 138
Fortin, S. M., Lipsky, R. K., Lhamo, R., Chen, J., Kim, E., Borner, T., Schmidt, H. D., & Hayes, M. R. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aay8071 · Cited by 127
“Site-specific Glp1r knockdown has been used to show the involvement of discrete GLP-1R populations in normal food intake and body weight regulation in rats (18, 32, 51).”
BackgroundKabahizi, A., Wallace, B., Lieu, L., Chau, D., Dong, Y., Hwang, E., & Williams, K. W. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15682 · Cited by 126
“For instance, vagal afferent GLP-1 receptor knockdown by RNA interference in rats increased meal size and was compensated for by a decrease in meal frequency such that 24-h food intake was not affected (Krieger et al., 2016).”
BackgroundActivation of murine pre-proglucagon–producing neurons reduces food intake and body weight
Gaykema, R. P., Newmyer, B. A., Ottolini, M., Raje, V., Warthen, D. M., Lambeth, P. S., Niccum, M., Yao, T., Huang, Y., Schulman, I. G., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci81335 · Cited by 123
Neural effects of gut‐ and brain‐derived glucagon‐like peptide‐1 and its receptor agonist
Katsurada, K., & Yada, T. (2016) · Journal of Diabetes Investigation · doi:10.1111/jdi.12464 · Cited by 119
“These effects were diminished with simultaneous central infusion of the GLP1 receptor antagonist exendin(9-39), and abolished in GLP-1 receptor knockout mice.”
BackgroundDo we know the true mechanism of action of the DPP ‐4 inhibitors?
Andersen, E. S., Deacon, C. F., & Holst, J. J. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13018 · Cited by 107
Mahapatra, M. K., Karuppasamy, M., & Sahoo, B. M. (2022) · Pharmaceutical Research · doi:10.1007/s11095-022-03302-1 · Cited by 110
G Protein–Coupled Receptors Targeting Insulin Resistance, Obesity, and Type 2 Diabetes Mellitus
Riddy, D. M., Delerive, P., Summers, R. J., Sexton, P. M., & Langmead, C. J. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014373 · Cited by 108
The potential and pitfalls of GLP-1 receptor agonists for renal protection in type 2 diabetes
Thomas, M. C. (2017) · Diabetes & Metabolism · doi:10.1016/s1262-3636(17)30069-1 · Cited by 111
Varin, E. M., Mulvihill, E. E., Baggio, L. L., Koehler, J. A., Cao, X., Seeley, R. J., & Drucker, D. J. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.05.055 · Cited by 104
“3380 Cell Reports 27, 3371–3384, June 11, 2019 post-meal glycemia and accelerated gastric emptying (Krieger et al., 2016).”
BackgroundPrinz, P., & Stengel, A. (2017) · Journal of Neurogastroenterology and Motility · doi:10.5056/jnm16194 · Cited by 118
“meal size and meal duration, whereas the number of meals was reduced and overall food intake not altered compared to controls.(96) Whether all these changes encompass GLP-1’s effects or reflect”
BackgroundThe hypothalamus for whole-body physiology: from metabolism to aging
Liu, T., Xu, Y., Yi, C.-X., Tong, Q., & Cai, D. (2022) · Protein & Cell · doi:10.1007/s13238-021-00834-x · Cited by 102
“Consistently, the feeding-suppressing effects of SCFAs require the intact vagal neurons, where GLP-1 and PYY are known to act (Baraboi et al., 2010; Krieger et al., 2015, 2016).”
BackgroundAlhadeff, A. L., Mergler, B. D., Zimmer, D. J., Turner, C. A., Reiner, D. J., Schmidt, H. D., Grill, H. J., & Hayes, M. R. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2016.246 · Cited by 102
“However, aside from a recent report demonstrating the requirement of vagal GLP-1R for food intake control (Krieger et al, 2016), the endogenous role of distinct GLP-1R subpopulations in the daily control of energy balance has not been explored.”
BackgroundA Role for GLP-1 in Treating Hyperphagia and Obesity
Grill, H. J. (2020) · Endocrinology · doi:10.1210/endocr/bqaa093 · Cited by 101
Raka, F., Farr, S., Kelly, J., Stoianov, A. M., & Adeli, K. (2019) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00036.2019 · Cited by 108
The therapeutic potential of GLP‐1 receptor biased agonism
Jones, B. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15497 · Cited by 98
Control of insulin secretion by GLP-1
Jones, B. J., Bloom, S. R., Buenaventura, T., Tomás, A., & Rutter, G. A. (2018) · Peptides · doi:10.1016/j.peptides.2017.12.013 · Cited by 105
Reappraising the role of the vagus nerve in GLP-1-mediated regulation of eating
Brierley, D. I., & de Lartigue, G. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15603 · Cited by 92
Dissecting the Role of Subtypes of Gastrointestinal Vagal Afferents
Wang, Y. B., de Lartigue, G., & Page, A. J. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.00643 · Cited by 103
Krieger, J.-P. (2020) · Peptides · doi:10.1016/j.peptides.2020.170342 · Cited by 91
“these vagal afferents subset is likely to mediate a negative vago-vagal feedback on gastric emptying, as supported by the findings of accelerated gastric emptying in vagal afferents Glp1r knockdown in rats [17] or Phox2b conditional Glp1r deletion in mice [57].”
InfluentialSelf-citationImmunologic impact of the intestine in metabolic disease
Winer, D. A., Winer, S., Dranse, H. J., & Lam, T. K. T. (2017) · Journal of Clinical Investigation · doi:10.1172/jci88879 · Cited by 86
“Intestinal cholecystokinin (CCK) and GLP-1 induce a gut/brain axis to control glucose homeostasis via vagal innervation (92, 93).”
BackgroundGhrelin Signaling Affects Feeding Behavior, Metabolism, and Memory through the Vagus Nerve
Davis, E. A., Wald, H. S., Suarez, A. N., Zubcevic, J., Liu, C. M., Cortella, A. M., Kamitakahara, A. K., Polson, J. W., Arnold, M., Grill, H. J., et al. (2020) · Current Biology · doi:10.1016/j.cub.2020.08.069 · Cited by 84
“Nodose ganglion injections were performed as previously described [3, 13].”
MethodSelf-citationGlucagon-Like Peptide-1 (GLP-1) in the Integration of Neural and Endocrine Responses to Stress
Diz-Chaves, Y., Herrera-Pérez, S., González-Matías, L. C., Lamas, J. A., & Mallo, F. (2020) · Nutrients · doi:10.3390/nu12113304 · Cited by 84
“All were together, suggesting that GLP-1 receptors in VANs contributed to the incretin-linked effects after a meal [191].”
BackgroundThe Role of the Gut Microbiota in the Gut–Brain Axis in Obesity: Mechanisms and Future Implications
van Son, J., Koekkoek, L. L., la Fleur, S. E., Serlie, M. J. M., & Nieuwdorp, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22062993 · Cited by 91
“Furthermore, GLP-1 exerts its effect on satiety and gastric emptying through GLP-1 receptors in the vagal nerve [120].”
BackgroundThe importance of estradiol for body weight regulation in women
Vigil, P., Meléndez, J., Petkovic, G., & Río, J. P. D. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.951186 · Cited by 96
Role of brain-gut-muscle axis in human health and energy homeostasis
Yin, Y., Guo, Q., Zhou, X., Duan, Y., Yang, Y., Gong, S., Han, M., Liu, Y., Yang, Z., Chen, Q., et al. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.947033 · Cited by 85
“Intestinal GLP-1 enters the blood and activates the brain by activating vagal afferent fibers, influencing feeding behavior and blood sugar levels (17).”
BackgroundHoldemanella biformis improves glucose tolerance and regulates GLP‐1 signaling in obese mice
Romaní‐Pérez, M., López‐Almela, I., Bullich‐Vilarrubias, C., Rueda‐Ruzafa, L., del Pulgar, E. M. G., Benítez‐Páez, A., Liebisch, G., Lamas, J. A., & Sanz, Y. (2021) · The FASEB Journal · doi:10.1096/fj.202100126r · Cited by 83
Regulation of body weight: Lessons learned from bariatric surgery
Albaugh, V. L., He, Y., Münzberg, H., Morrison, C. D., Yu, S., & Berthoud, H. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2022.101517 · Cited by 83
Learning of food preferences: mechanisms and implications for obesity & metabolic diseases
Berthoud, H., Morrison, C. D., Ackroff, K., & Sclafani, A. J. (2021) · International Journal of Obesity · doi:10.1038/s41366-021-00894-3 · Cited by 95
Xie, C., Qi, C., Zhang, J., Wang, W., Meng, X., Aikepaer, A., Lin, Y., Su, C., Liu, Y., Feng, X., et al. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.116791 · Cited by 76
The role of the vagus nerve in appetite control: Implications for the pathogenesis of obesity
Cork, S. C. (2018) · Journal of Neuroendocrinology · doi:10.1111/jne.12643 · Cited by 77
Holst, J. J., Albrechtsen, N. J. W., Rosenkilde, M. M., & Deacon, C. F. (2019) · Comprehensive Physiology · doi:10.1002/cphy.c180013 · Cited by 54
Bifari, F., Manfrini, R., Dei Cas, M., Berra, C., Siano, M., Zuin, M., Paroni, R., & Folli, F. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.09.025 · Cited by 69
Imai, J., & Katagiri, H. (2021) · International Immunology · doi:10.1093/intimm/dxab023 · Cited by 80
Glucagon-like peptide-1 regulates brown adipose tissue thermogenesis via the gut-brain axis in rats
Krieger, J.-P., Santos da Conceição, E. P., Sanchez-Watts, G., Arnold, M., Pettersen, K. G., Mohammed, M., Modica, S., Lossel, P., Morrison, S. F., Madden, C. J., et al. (2018) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00068.2018 · Cited by 63
“Fourteen rats (260–315 g) were used to generate VAN Glp1r kd and control animals as previously described (25).”
BackgroundMethodInfluentialSelf-citationXie, C., Jones, K. L., Rayner, C. K., & Wu, T. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12090790 · Cited by 67
“be mediated primarily via vagal afferents [68,69] and the activation of GLP-1 receptors in the central nervous system [70,71].”
BackgroundJalleh, R. J., Marathe, C. S., Rayner, C. K., Jones, K. L., Umapathysivam, M. M., Wu, T., Quast, D. R., Plummer, M. P., Nauck, M. A., & Horowitz, M. (2024) · Endocrinology · doi:10.1210/endocr/bqae155 · Cited by 61
Ren, W., Chen, J., Wang, W., Li, Q., Yin, X., Zhuang, G., Zhou, H., & Zeng, W. (2024) · Neuron · doi:10.1016/j.neuron.2023.12.012 · Cited by 68
The gut microbiota to the brain axis in the metabolic control
Grasset, E., & Burcelin, R. (2019) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-019-09511-1 · Cited by 58
The effects of GLP-1 agonists on musculoskeletal health and orthopedic care
Gatto, A., Liu, K., Milan, N., & Wong, S. (2025) · Current Reviews in Musculoskeletal Medicine · doi:10.1007/s12178-025-09978-3 · Cited by 55
A critical role of hepatic GABA in the metabolic dysfunction and hyperphagia of obesity
Geisler, C. E., Ghimire, S., Bruggink, S. M., Miller, K. E., Weninger, S. N., Kronenfeld, J. M., Yoshino, J., Klein, S., Duca, F. A., & Renquist, B. J. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109301 · Cited by 62
Gut Microbiome Regulation of Gut Hormone Secretion
Chao, J. L., Coleman, R. A., Keating, D. J., & Martin, A. M. (2025) · Endocrinology · doi:10.1210/endocr/bqaf004 · Cited by 64
The elusive cephalic phase insulin response: triggers, mechanisms, and functions
Langhans, W., Watts, A. G., & Spector, A. C. (2022) · Physiological Reviews · doi:10.1152/physrev.00025.2022 · Cited by 59
Self-citationNovel developments in vagal afferent nutrient sensing and its role in energy homeostasis
de Lartigue, G., & Diepenbroek, C. (2016) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2016.08.007 · Cited by 53
Lu, V. B., Rievaj, J., O’Flaherty, E. A., Smith, C. A., Pais, R., Pattison, L. A., Tolhurst, G., Leiter, A. B., Bulmer, D. C., Gribble, F. M., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09045-9 · Cited by 52
How dietary amino acids and high protein diets influence insulin secretion
Yanagisawa, Y. (2023) · Physiological Reports · doi:10.14814/phy2.15577 · Cited by 58
Opposite Regulation of Ghrelin and Glucagon-like Peptide-1 by Metabolite G-Protein-Coupled Receptors
Engelstoft, M. S., & Schwartz, T. W. (2016) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2016.07.001 · Cited by 61
Vagal Nerve Stimulation for Glycemic Control in a Rodent Model of Type 2 Diabetes
Yin, J., Ji, F. Y., Gharibani, P. M., & Chen, J. D. Z. (2019) · Obesity Surgery · doi:10.1007/s11695-019-03901-9 · Cited by 59
“Vagal afferent neurons may therefore relay the gut GLP-1derived signals to the brain and mediate satiating and glucoregulatory responses [48].”
Fu, Z., Gong, L., Liu, J., Wu, J., Barrett, E. J., Aylor, K. W., & Liu, Z. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.00555 · Cited by 50
Clarke, G. S., Page, A. J., & Eldeghaidy, S. (2024) · Pharmacology Research & Perspectives · doi:10.1002/prp2.70027 · Cited by 55
Connecting the Gut Microbiota and Neurodegenerative Diseases: the Role of Bile Acids
Wang, S., Xu, C., Liu, H., Wei, W., Zhou, X., Qian, H., Zhou, L., Zhang, H., Wu, L. M., Chen, Z., et al. (2023) · Molecular Neurobiology · doi:10.1007/s12035-023-03340-9 · Cited by 54
Ghrelin and Glucagon-Like Peptide-1: A Gut-Brain Axis Battle for Food Reward
Decarie-Spain, L., & Kanoski, S. E. (2021) · Nutrients · doi:10.3390/nu13030977 · Cited by 45
“Both ghrelin and GLP-1 affect food intake and metabolism via multiple biological pathways, including a paracrine vagus nerve pathway [4,5], blood-to-brain signaling, and in the case of GLP-1, projections from the GLP-1-producing preproglucagon neurons in the NTS throughout the neuraxis [6].”
BackgroundQin, W., Ying, W., Hamaker, B., & Zhang, G. (2021) · Comprehensive Reviews in Food Science and Food Safety · doi:10.1111/1541-4337.12808 · Cited by 48
Dorton, H. M., Luo, S., Monterosso, J. R., & Page, K. A. (2018) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2017.00297 · Cited by 47
“Reduced expression of GLP-1 receptor in vagal afferents leads to increases in food intake and post-feeding blood glucose levels in rats (57).”
BackgroundBrainstem GLP-1 signalling contributes to cancer anorexia-cachexia syndrome in the rat
Borner, T., Liberini, C. G., Lutz, T. A., & Riediger, T. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.12.024 · Cited by 46
GLP-1 and the Neurobiology of Eating Control: Recent Advances
Jones, L. A., & Brierley, D. I. (2025) · Endocrinology · doi:10.1210/endocr/bqae167 · Cited by 43
“Given the role of GLP-1R-expressing VANs in physiological satiation (23, 39), reduced gut GLP-1 secretion and/or decreased vagal sensitivity to GLP-1 could conceivably be part of a vagal contribution to the impaired satiation reported in people living with obesity (135).”
Chen, Y. P., Ding, Z., Yu, Y., He, P., Zhou, Y., Liu, Y., & Feng, X. (2023) · Trends in Food Science & Technology · doi:10.1016/j.tifs.2023.06.019 · Cited by 45
Ahmed, I. A. B. (2024) · Journal of Obesity · doi:10.1155/2024/8056440 · Cited by 52
“Teir method employed lentiviral-mediated knockdown of these receptors in male Sprague Dawley rats that led to an increase in food consumption and hastened gastric emptying, resulting in heightened postprandial glycemia as well as insulin secretion [29].”
GPR40 reduces food intake and body weight through GLP-1
Gorski, J. N., Pachanski, M. J., Mane, J., Plummer, C. W., Souza, S., Thomas-Fowlkes, B. S., Ogawa, A. M., Weinglass, A. B., Salvo, J. D., Cheewatrakoolpong, B., et al. (2017) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00435.2016 · Cited by 45
“However, GLP-1 may also delay gastric emptying via paracrine effects through vagal afferents, which can occur after physiological elevations in endogenous levels and may be observed with acute administration of GLP-1 analogs (14, 15).”
BackgroundMcDougle, M., Quinn, D., Diepenbroek, C., Singh, A., de la Serre, C., & de Lartigue, G. (2021) · Acta Physiologica · doi:10.1111/apha.13530 · Cited by 42
Blunted Vagal Cocaine- and Amphetamine-Regulated Transcript Promotes Hyperphagia and Weight Gain
Lee, S. J., Krieger, J.-P., Vergara, M., Quinn, D., McDougle, M. J., de Araujo, A., Darling, R. A., Zollinger, B., Anderson, S., Pan, A., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.01.045 · Cited by 42
“5 mL viral solution into each NG with a Picospritzer III injector (Parker Hannifin) as previously described (Krieger et al., 2016).”
Self-citationJalleh, R. J., Talley, N. J., Horowitz, M., & Nauck, M. A. (2026) · Journal of Clinical Investigation · doi:10.1172/jci194740 · Cited by 40
Protein- and Calcium-Mediated GLP-1 Secretion: A Narrative Review
Watkins, J. D., Koumanov, F., & Gonzalez, J. T. (2021) · Advances in Nutrition · doi:10.1093/advances/nmab078 · Cited by 40
Plasticity of gastrointestinal vagal afferent satiety signals
Page, A. J., & Kentish, S. J. (2016) · Neurogastroenterology & Motility · doi:10.1111/nmo.12973 · Cited by 40
Glucose effectiveness: Lessons from studies on insulin‐independent glucose clearance in mice
Åhrén, B., & Pacini, G. (2020) · Journal of Diabetes Investigation · doi:10.1111/jdi.13446 · Cited by 43
Gastrointestinal autonomic neuropathy in diabetes
Marathe, C. S., Jones, K. L., Wu, T., Rayner, C. K., & Horowitz, M. (2020) · Autonomic Neuroscience · doi:10.1016/j.autneu.2020.102718 · Cited by 38
Neuroendocrine gut–brain signaling in obesity
Gruber, T., Lechner, F., Krieger, J.-P., & García‐Cáceres, C. (2024) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2024.05.002 · Cited by 44
“…glicentin 2 – 20 pM Potentiation of glucose-stimulated insulin secretion (incretin effect), inhibition of food intake, delay of gastric emptying [96] I-cells, upper intestine CCK 1 – 10 pM Acute suppression of food intake [7,38], increased activity of brainstem neurons in response to gastric…”
BackgroundSelf-citationNakamura, U., Nohmi, T., Sagane, R., Hai, J., Ohbayashi, K., Miyazaki, M., Yamatsu, A., Kim, M., & Iwasaki, Y. (2022) · Nutrients · doi:10.3390/nu14122492 · Cited by 44
“GLP-1 released by meals and food ingredients, such as the rare sugar D-allulose, activate a subclass of vagal afferent neurons expressing GLP-1 receptor, thereby inducing satiation, enhancing insulin secretion, and regulating glucose metabolism [19,48].”
BackgroundHoffman, S., ALVARES, D. C. L., & Adeli, K. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2022.101590 · Cited by 47
“The role of these GLP-1R-containing vagal afferent neurons in regulating peripheral metabolism has been evidenced previously by GLP-1R knockdown in the vagal afferent nerves of rats, which display increased food consumption, accelerated gastric emptying, and post-meal glycemia coupled with depressed insulin secretion…”
Background
Metadata
- Authors
- Krieger, J.-P., Arnold, M., Pettersen, K. G., Lossel, P., Langhans, W., & Lee, S. J.
- Affiliations
- ETH Zurich (CH)
- Corresponding author
- Krieger, Jean-Philippe
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2015-10-15
- Volume
- 65
- Issue
- 1
- Pages
- 34-43
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2180065345
- Cited by
- 269
- References
- 43
- Citations by year
- 2026: 24 · 2025: 30 · 2024: 36 · 2023: 15 · 2022: 19 · 2021: 33 · 2020: 26 · 2019: 21 · 2018: 24 · 2017: 23 · 2016: 17 · 2015: 1
- FWCI
- 12.01
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes (publishedVersion)
- PubMed (publishedVersion)
- Funders
- ETH Zurich (4712-2)
- Topics
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Keywords
- GLP-1 receptor, vagal afferent neurons, nodose ganglion, gene knockdown, dietary intake, glycemia, insulin secretion, gastric emptying, meal size, energy homeostasis, enteroendocrine L cells
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Insulin Secretion, Animals, Blood Glucose, Eating, Energy Metabolism, Gastric Emptying, Insulin, Intestines, Male, Neurons, Afferent, Nodose Ganglion, Vagus Nerve, Rats, Sprague-Dawley, Postprandial Period, Rats, Gene Knockdown Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.